Drag Pharma
Go back
Download Datasheet

Dermisolona® Oral suspension

Steroid anti-inflammatory - Antiallergic

It is indicated as an aid in the treatment of inflammatory and allergic disorders in dogs and cats. In dogs it is also indicated as an immunosuppressant in autoimmune diseases, as therapy for chronic inflammatory bowel disease and in the treatment of hypoadrenocorticism.

Data Sheet

Oral suspension.

Steroid anti-inflammatory – Antiallergic.

Dogs and cats.

Each mL of oral suspension contains:
Prednisolone Acetate…………………………..4.5 mg
(Equivalent to 4 mg of Prednisolone base)
Excipients q.s………………………………………….1 mL

It is indicated as an aid in the treatment of inflammatory and allergic disorders in dogs and cats. In dogs it is also indicated as an immunosuppressant in autoimmune diseases, as therapy for chronic inflammatory bowel disease and in the treatment of hypoadrenocorticism.

Oral administration.

Shake the suspension before use, then extract the dose of product with the measuring syringe or dropper and administer directly into the oral cavity.

DOSAGE OF THE ACTIVE INGREDIENTPRODUCT DOSAGE. (1 mL = 26 drops of product)
ANTI-INFLAMMATORY AND ANTI-ALLERGIC THERAPYDOGS0.5 to 1 mg/kg of weight, every 12 to 24 hours, for 3 to 5 days.1.5 to 2.5 mL per 10 kg of weight, or 4 to 7 drops per kg of weight, every 12 to 24 hours, for 3 to 5 days.
CATS1 to 2 mg/kg of weight, every 12 to 24 hours, for 3 to 5 days.1.5 to 2.5 mL per 5 kg of weight or 7 to 13 drops per kg of weight, every 12 to 24 hours, for 3 to 5 days.
In prolonged treatments, it is recommended to reduce the effective dose to the lowest effective dose and administer it every other day in the morning for dogs, and in the afternoon for cats (to respect the circadian rhythm).In prolonged treatments, it is recommended to reduce the effective dose to the lowest effective dose and administer it every other day in the morning for dogs, and in the afternoon for cats (to respect the circadian rhythm).
IMMUNOSUPPRESSANTDOGS1 to 4 mg/Kg/ every 24 hours for 2 to 14 days. Then, 0.5 to 2 mg/Kg/ every 24 hours, for 14 days. Then reduce the dose at regular intervals (2 to 6 weeks), until reaching the maintenance dose of 0.5 to 1 mg/Kg/alternate days. (*)2.5 to 10 mL per 10 kg of weight per day, or 7 to 26 drops per kg of weight every 24 hours, for 2 to 14 days. Then, 1.3 to 5 mL per 10 kg of weight per day, or 4 to 13 drops per kg of weight every 24 hours, for 2 to 14 days. Then reduce the dose at regular intervals (2 to 6 weeks), until reaching the maintenance dose of 1.5 to 2.5 mL per 10 kg of weight, or 4 to 7 drops per kg of weight, on alternate days. . (*)(**)
CHRONIC INFLAMMATORY BOWEL DISEASEDOGS1 to 4 mg/kg body weight every 12 to 24 hours for 2 to 4 weeks, then slowly reduce the dose at intervals of 10 days to 2 weeks depending on clinical response, until reaching a maintenance dose of 0.5 to 1 mg/Kg every other day (*)2.5 to 10 mL per 10 kg of weight per day, or 7 to 26 drops per kg of weight, every 12 to 24 hours, for 2 to 4 weeks, then slowly reduce the dose at intervals of 10 to 2 days. weeks depending on the clinical response, until reaching the maintenance dose of 1.5 to 2.5 mL per 10 kg of weight, or 4 to 7 drops per kg of weight, on alternate days. (*)(**)
HYPOADRENOCORTICISMDOGS0.2 to 0.4 mg/kg of weight, every 24 hours, permanently.0.5 to 1 mL per 10 kg of weight or 2 to 3 drops per kg of weight every 24 hours, permanently.
(*) The duration of therapy varies depending on the intensity of the condition and the remission of symptoms, and may last for several weeks or months. In these cases, it is recommended to use the minimum effective dose, on an alternate day basis. (**) 1 mL of Dermisolone® Oral Suspension is equivalent to 26 drops of product.
  • Administered short-term, Prednisolone is unlikely to cause harmful effects, even in massive doses. Adverse effects are generally associated with chronic therapies, especially at high doses or if an alternate-day regimen is not followed.
  • The most common adverse effects are polyuria, polydipsia and polyphagia; and are preferably associated with anti-inflammatory doses.
  • Regarding immunosuppressive doses and extensive treatments, adverse reactions are more likely to occur and potentially more pronounced. These effects, observable on rare occasions, manifest as symptoms of hyperadrenocorticism (Cushing’s Syndrome): dull and dry coat, weight gain, panting, vomiting, diarrhea, hepatomegaly with the consequent alteration of the concentration of liver enzymes in the serum, pancreatitis, gastrointestinal ulceration (particularly when used with NSAIDs), lipidemia, alteration of insulin requirements, activation or intensification of Diabetes Mellitus, muscle wasting and behavioral changes (depression, lethargy, vices).
  • In prolonged treatments, an increase in the incidence of osteoporosis is described, especially in older dogs.
  • In case of prolonged treatments with Prednisolone, a greater protein intake should be provided to keep the animal in a positive nitrogen balance.
  • A delaying effect on wound healing has not been described, however, such a possibility should be considered when used in surgery.
  • Prolonged therapy with glucocorticoids can suppress adrenocortical activity, so its suspension should be carried out gradually to ensure the gradual return of ACTH and endogenous corticosteroid functions.
  • Administer with caution to animals that have diabetes, osteoporosis or are recovering from a bone fracture, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal failure or active tuberculosis.
  • The anti-inflammatory effects can mask signs of infection.
  • Administer with caution to growing animals as it may cause retardation.
  • Administer with caution to animals with liver failure.
  • Do not use in animals with Cushing’s syndrome.
  • Do not use in patients with systemic fungal infections or viral infections.
  • Do not use in animals with peptic or corneal ulcer.
  • Do not administer to pregnant females.
  • Do not use in animals hypersensitive to any of the components of this product.
  • Do not administer together with vaccines.

Keep out of the reach of children.

Do not administer to pregnant or lactating females.

It is recommended to avoid the concomitant administration of Prednisolone with:

  • Amphotericin B or kaliuretic diuretics (furosemide, thiazides), as hypokalemia may occur. Digitalis may increase the possibility of toxicity if hypokalemia occurs.
  • Phenytoin, phenobarbital and Rifampin, because they can increase the metabolism of corticosteroids.
  • Ciclosporine, because blood levels of both drugs can be increased with mutual inhibition of hepatic metabolism.
  • With ulcerogenic drugs (for example, non-steroidal anti-inflammatory drugs) as the risk of gastrointestinal ulceration may increase.
  • Cyclophosphamide, since corticosteroids can inhibit the hepatic metabolism of the chemotherapy drug.
  • Patients treated with corticosteroids at immunosuppressive doses should generally not receive live attenuated virus vaccines, because viral replication may be enhanced.
  • Insulin requirements may be increased in patients receiving glucocorticoids.

Given short-term, glucocorticoids are unlikely to cause harmful effects, even in massive doses. Adverse effects are generally associated with chronic therapies, especially at high doses or if an alternate-day regimen is not followed.

  • In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water.
  • In case of irritation, go to a medical center and show the product insert.
  • In case of accidental ingestion, go immediately to a medical center and show the product insert.
  • Do not handle by pregnant women.

Store in a cool, dry place, at a temperature between 2 and 30º C.
Once the bottle is opened, use within 30 days.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product remains on the ground or in water courses. For expired or unused products, contact the manufacturing laboratory.

VETERINARY USE
SHAKE BEFORE USE

Sale under Veterinary Medical prescription.

Reg. SAG N° 2281

Container with 30 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.

SKU: a4d2f0d23dcc Categories: , Tags: , , , , , ,
*Important:

You have accessed information referring to pharmaceutical products authorized for sale under a medical prescription. In accordance with Chilean legislation, the promotion and advertising of these products is restricted to professionals who prescribe and dispense them. The information contained on this page is specialized technical and scientific information.

Related
Products